IP Verse

Syringe

Patent No. EP2869813 (titled "Syringe") was filed by Novartis on Jan 25, 2013. The application was issued on Nov 21, 2018.

Patent Summary

A terminally sterilized, pre-filled syringe for intravitreal injection comprises a glass barrel, a stopper, and a plunger. The plunger forces the stopper toward the outlet to expel an ophthalmic solution containing ranibizumab from a variable volume chamber. The syringe is characterized by a nominal maximum fill volume of approximately 0.5ml, containing a dosage volume between 0.03ml and 0.05ml of ranibizumab. The barrel contains 5µg to 100µg of silicone oil, and the solution contains $\le$2 particles $\ge$50µm in diameter per ml. With a 30G x 0.5 inch needle attached, the syringe exhibits a stopper break loose force of 2N to 5N, measured at a traveling speed of 190mm/min over a travel length of 10.9 mm.

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
DILGAug 21, 2019KEIL & SCHAAFHAUSEN PATENTANWALTE PARTGMBB
HOFFMANN EITLEAug 21, 2019HOFFMANN EITLE
SPILGIES, JAN-HENDRIK, C/O HOFFMAN - EITLEAug 21, 2019HOFFMANN EITLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP2869813

NOVARTIS
Application Number
EP13701276A
Filing Date
Jan 25, 2013
Status
Revoked
Jul 29, 2022
Publication Date
Nov 21, 2018
External Links
Slate, Register , Google Patents